|
||||||||||||||||||||||||||
| | SEC Info | |
| | Home | |
| | Search | |
| | My Interests | |
| | Help | |
| | Sign In | |
| | Please Sign In |
|
||||||||||||||||||||||||||
As Of Filer Filing As/For/On Docs:Pgs Issuer Agent
6/23/05 Biomarin Pharmaceutical Inc 8-K{8,9} 6/21/05 3:7 1193125
Document/Exhibit Description Pages Size
1: 8-K Current Report HTML 21K
2: EX-99.1 Press Release HTML 23K
3: EX-99.2 Press Release Regarding the Appointment of Stephen HTML 17K
Aselage
| Form 8-K |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 21, 2005
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-26727 | 68-0397820 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (IRS Employer Identification No.) |
| 105 Digital Drive, Novato, California | 94949 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (415) 506-6700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On June 21, 2005, BioMarin Pharmaceutical Inc. (the “Company”) issued two press releases. One release related to the U.S. launch of Naglazyme for MPS VI and the second related to the appointment of Stephen Aselage as the Company’s Senior Vice President of Global Commercial Operations. The Company’s press releases issued on June 21, 2005 are attached hereto as Exhibits 99.1 and 99.2, respectively. The initial wholesale acquisition price for Naglazyme in the United States is $1,450 per 5mg vial.
Item 9.01. Financial Statements, Pro Forma Financial Statements and Exhibits.
| (a) | Financial Statements of Business Acquired. |
Not Applicable.
| (b) | Pro Forma Financial Information. |
Not Applicable.
| (c) | Exhibits. |
| Exhibit 99.1 | Press Release of the Company dated June 21, 2005 regarding the U.S. launch of Naglazyme for MPS VI. | |
| Exhibit 99.2 | Press Release of the Company dated June 21, 2005 regarding the appointment of Stephen Aselage as the Company’s Senior Vice President of Global Commercial Operations. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc., a Delaware corporation | ||||
| Date: June 22, 2005 | By: | /s/ G. Eric Davis | ||
| Vice President, Corporate Counsel | ||||
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press Release of the Company dated June 21, 2005 regarding the U.S. launch of Naglazyme for MPS VI. | |
| Exhibit 99.2 | Press Release of the Company dated June 21, 2005 regarding the appointment of Stephen Aselage as the Company’s Senior Vice President of Global Commercial Operations. | |
| This 8-K Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| For The Period Ended | 6/21/05 | PRE 14A | ||
| 6/22/05 | ||||
| Filed On / Filed As Of | 6/23/05 | |||
| Top | List All Filings | |||